多囊卵巢综合征并胰岛素抵抗大鼠高分子脂联素表达及二甲双胍的影响

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (822 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨高分子脂联素(HMW APN)在多囊卵巢综合征(PCOS)并胰岛素抵抗大鼠中的变化及二甲双胍对其影响。方法 40只SD大鼠随机平均分成正常组(NC组)、胰岛素抵抗组(IR组)、PCOS组、PCOS-IR组,后两组采用来曲唑灌胃法造模,通过连续阴道涂片判断造模成功与否。建模成功后,PCOS-IR组给予二甲双胍(0.5mg/g),NC组、IR组、PCOS组均给予等体积的生理盐水。干预末口服葡萄糖耐量试验测定血糖及胰岛素;阴道涂片、吉姆萨染色观察动情周期;放射免疫法检测促卵泡生成素、促黄体生成素、睾酮;酶联免疫吸附测定法检测HMW APN、胰岛素水平;卵巢组织HE染色,观察卵巢形态变化;RT-PCR检测卵巢组织中Adiponectin、AdipoR1、AdipoR2表达水平。结果 PCOS组和PCOS-IR组无明显的动情周期,呈无排卵状态;血清睾酮、黄体生成素水平分泌增加,呈高雄激素、高黄体生成素状态,卵巢多囊样变;两组均出现的糖耐量异常,空腹胰岛素、胰岛素抵抗指数均高于NC组;二甲双胍干预后,IR组、PCOS组血清HMW APN水平均较NC组减低(P＜0.05),PCOS-IR组血清HMW APN水平与NC组比较未见差异(P>0.05),而较PCOS组和IR组增加(P＜0.05);PCOS-IR组HMW APN mRNA表达较PCOS组减低(P＜0.05)。结论血清HMW APN在PCOS-IR、PCOS大鼠中表达减低;二甲双胍可以调节糖代谢水平,减轻PCOS大鼠卵巢多囊性改变,提高HMW APN水平,从而达到改善PCOS-IR大鼠代谢状态的目的。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张莉
	高旭峰
	王玉环

关键词 ：多囊卵巢综合征, 高分子脂联素, 二甲双胍, 胰岛素抵抗

收稿日期: 2018-01-10

基金资助:陕西省科技攻关项目(2016SF-007)

通讯作者: 王玉环(wangyuhuan369@126.com)

引用本文:

张莉,高旭峰,王玉环. 多囊卵巢综合征并胰岛素抵抗大鼠高分子脂联素表达及二甲双胍的影响[J]. 中国生育健康杂志, 2019, 30(1): 72-76.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2019/V30/I1/72

1 Amato MC,Vesco R,Vigneri E,et al.Hyperinsulinism and polycystic ovary syndrome (PCOS):role of insulin clearance.J Endocrinol Invest,2015,38:1319-1326.
2 Chen TS,Chen YT,Liu CH,et al.Effect ofchromium supplementation on element distribution in a mouse model of polycystic ovary syndrome.Biol Trace Elem Res,2015,168:472-480.
3 Sevil C,Berfu D,Sezin EA,et al.Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome.Fertil Steril,2014,102:826-830.
4 Hossain MM,Mukheem A,Kamarul T.The prevention and treatment of hypoadiponectinemia associated human diseases by up-regulation of plasma adiponectin.Life Sci,2015,135:55-67.
5 Kafali H,Iriadam M,Ozardali I,et al.Letrozole-induced polycystic ovaries in the rat:a new model for cystic ovarian disease.Arch Med Res,2004,35:103-108.
6 Gozukara IO,Pinar N,Ozcan O,et al.Effect of colchicine on polycystic ovary syndrome:an experimental study.Arch Gynecol Obstet,2016,293:675-680.
7 Harati M,Ani M.Vanadyl sulfate ameliorates insulin resistance and restores plasma dehydroepiandrosterone-sulfate levels in fructose-fed,insulin-resistant rats.Clin Biochem,2004,37:694-697.
8 Pischon T,Lahmann PH,Boeing H,et al.Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC).J Natl Cancer Inst,2006,98:920-931.
9 Alberti KG,Zimmet P,Shaw J.Metabolic syndrome--a new world-wide definition.A Consensus Statement from the International Diabetes Federation.Diabet Med,2006,23:469-480.
10 李明明,潘文,康开彪.不同造模方法对大鼠多囊卵巢综合征伴胰岛素抵抗模型的影响.西部中医药,2015.4:11-14.
11 Aroda V,Ciaraldi TP,Chang SA,et al.Circulating and cellular adiponectin in polycystic ovary syndrome:relationship to glucose tolerance and insulin action.Fertil Steril,2008,89:1200-1208.
12 Connor AO,Phelan N,Tun TK,et al.High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance.J Clin Endocrinol Metab,2010,95:1378-1385.
13 Wickham ER,Cheang KI,Clore JN,et al.Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome.Metabolism,2011,60:366-372.
14 Glintborg D,Frystyk J,Hjlund K,et al.Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.Clin Endocrinol,2007,68:165-174.